Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Uh fourth quarter results are out from Fizer. Earnings came [music] in at 60 cents a share. 66 cents a share I should say.That beat expectations of 67 cents. Revenue of 17.6% billion also beat expectations for the full year. Fizer is affirming its revenue and earnings guidance.And separately, Fizer just put out with positive just put out some positive results from a phase 2b trial of its injectable GLP weight loss GLP1 weight loss drug. That study found that patients continued robust weight loss when switch ...